Update on the diagnosis and management of Wilson disease
EA Roberts - Current gastroenterology reports, 2018 - Springer
Abstract Purpose of Review Exciting developments relating to Wilson disease (WD) have
taken place with respect to both basic biological and clinical research. This review critically …
taken place with respect to both basic biological and clinical research. This review critically …
[HTML][HTML] Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada
Suboxone (buprenorphine-naloxone) is an opioid product approved in the US and Canada
for the treatment of opioid use disorder. The drug is considered an important response to the …
for the treatment of opioid use disorder. The drug is considered an important response to the …
[HTML][HTML] Cost-based price calculation of mexiletine for nondystrophic myotonia
S van den Berg, V van der Wel, SJ de Visser… - Value in Health, 2021 - Elsevier
Objectives Mexiletine is a long-known drug used for the treatment of arrhythmias and
repurposed in the 1980s for patients with nondystrophic myotonia (NDM). Recently, the price …
repurposed in the 1980s for patients with nondystrophic myotonia (NDM). Recently, the price …
[HTML][HTML] Literature Review on Health Emigration in Rare Diseases—A Machine Learning Perspective
The article deals with one of the effects of health inequalities and gaps in access to
treatments for rare diseases, namely health-driven emigration. The purpose of the paper is …
treatments for rare diseases, namely health-driven emigration. The purpose of the paper is …
[HTML][HTML] The Impact of Suboxone's Market Exclusivity on Cost of Opioid Use Disorder Treatment
Background Buprenorphine-naloxone is an essential part of the response to opioid
poisoning rates in North America. Manipulating market exclusivity is a strategy …
poisoning rates in North America. Manipulating market exclusivity is a strategy …
High-cost drugs for rare diseases: their expenditure and value based on a regional area-based study
S Manea, L Visonà Dalla Pozza… - Health Services …, 2024 - journals.sagepub.com
Background: in the field of rare diseases (RDs) most of the European studies on budget
impact analysis of drugs that have been conducted often lay on theoretical assumptions and …
impact analysis of drugs that have been conducted often lay on theoretical assumptions and …
Does an orphan drug policy make a difference in access? A comparison of Canada and Australia
J Lexchin, N Moroz - International Journal of Health Services, 2020 - journals.sagepub.com
Canada has been discussing whether to implement an orphan drug policy for more than 25
years. Recently, the federal government announced funding for orphan drugs starting in …
years. Recently, the federal government announced funding for orphan drugs starting in …
Reforming Canada's Special Access Programme (SAP) to improve access to off-patent essential medicines
AR Houston, CM Blais, S Houston… - Official Journal of the …, 2018 - jammi.utpjournals.press
Many essential medicines, including basic drugs such as albendazole, do not have approval
to be marketed in Canada. Instead, they are only available through a federal government …
to be marketed in Canada. Instead, they are only available through a federal government …
[PDF][PDF] Hubungan Tingkat Stres dengan Peningkatan Kadar Gula Darah Pada Pasien Diabetes Mellitus Tipe 2 di Poli Penyakit Dalam RSUD Kabupaten Bintan Tahun …
ABSTRAK Menurut data RSUD Kabupaten Bintan tahun 2017 DM tipe 2 menduduki urutan
tingkat pertama dalam sepuluh penyakit terbesar. Berdasarkan data pada tahun 2018 DM …
tingkat pertama dalam sepuluh penyakit terbesar. Berdasarkan data pada tahun 2018 DM …
[PDF][PDF] Evidence and Policy in Pharmaceutical Regulation: The promise of, and barriers to, a system of adaptive licensing
K Fierlbeck, M Herder - International Conference on Public …, 2015 - ippapublicpolicy.org
In the regulation of pharmaceutical products, there is growing interest in moving to an
“adaptive licensing”(AL) model. Eichler et al.(2012) describe “adaptive licensing” as …
“adaptive licensing”(AL) model. Eichler et al.(2012) describe “adaptive licensing” as …